Bicycle Therapeutics PLC
NASDAQ:BCYC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.52
27.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC
Cash Taxes Paid
Bicycle Therapeutics PLC
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash Taxes Paid
$694k
|
CAGR 3-Years
98%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash Taxes Paid
$2.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Cash Taxes Paid
-£29.2m
|
CAGR 3-Years
-92%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash Taxes Paid
$551k
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash Taxes Paid
£977k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
69%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash Taxes Paid
£21.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
Bicycle Therapeutics PLC
Glance View
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 119 full-time employees. The company went IPO on 2019-05-23. The firm is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets membrane type 1 matrix metalloproteinase (MT1-MMP) is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the center for drug development of cancer research United Kingdom. The Company’s immune-oncology products include BT7480, BT7455 and BT7401. BT7480 is a TICA that targets CD137 and Nectin-4. BT7455 is a TICA targeting EphA2 and CD137. BT7401 is an agonistic Bicycle built from multiple CD137 monomeric Bicycles.
See Also
What is Bicycle Therapeutics PLC's Cash Taxes Paid?
Cash Taxes Paid
694k
USD
Based on the financial report for Sep 30, 2024, Bicycle Therapeutics PLC's Cash Taxes Paid amounts to 694k USD.
What is Bicycle Therapeutics PLC's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 5Y
58%
Over the last year, the Cash Taxes Paid growth was -59%. The average annual Cash Taxes Paid growth rates for Bicycle Therapeutics PLC have been 98% over the past three years , 58% over the past five years .
You don't have any saved screeners yet
